Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.yjmcc.2020.07.003 http://scihub22266oqcxt.onion/10.1016/j.yjmcc.2020.07.003 32681845!7362808!32681845     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32681845&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Mol+Cell+Cardiol 2020 ; 146 (ä): 32-40 Nephropedia Template TP {{tp|p=32681845|t=2020. Coagulopathy in COVID-19: Focus on vascular thrombotic events |pdf=|usr=}}{{32681845}} gab.com Text Coagulopathy in COVID-19: Focus on vascular thrombotic events JO: J Mol Cell Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=32681845 #FOAvip SARS-CoV-2 causes a phenotype of pneumonia with diverse manifestation, which is termed as coronavirus disease 2019 (COVID-19). An impressive high transmission rate allows COVID-19 conferring enormous challenge for clinicians worldwide, and developing to a pandemic level. Combined with a series of complications, a part of COVID-19 patients progress into severe cases, which critically contributes to the risk of fatality. To date, coagulopathy has been found as a prominent feature of COVID-19 and severe coagulation dysfunction may be associated with poor prognosis. Coagulopathy in COVID-19 may predispose patients to hypercoagulability-related disorders including thrombosis and even fatal vascular events. Inflammatory storm, uncontrolled inflammation-mediated endothelial injury and renin angiotensin system (RAS) dysregulation are the potential mechanisms. Ongoing efforts made to develop promising therapies provide several potential strategies for hypercoagulability in COVID-19. In this review, we introduce the clinical features of coagulation and the increased vascular thrombotic risk conferred by coagulopathy according to present reports about COVID-19. The potential underlying mechanisms and emerging therapeutic avenues are discussed, emphasizing an urgent need for effective interventions. Twit Text FOAVip Coagulopathy in COVID-19: Focus on vascular thrombotic events ????J Mol Cell Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=32681845 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32681845 #FOAvip English Wikipedia <ref>{{Cite pmid|32681845}}</ref> Coagulopathy in COVID-19: Focus on vascular thrombotic events #MMPMID32681845 Shi W; Lv J; Lin L J Mol Cell Cardiol 2020[Sep]; 146 (ä): 32-40 PMID32681845show ga SARS-CoV-2 causes a phenotype of pneumonia with diverse manifestation, which is termed as coronavirus disease 2019 (COVID-19). An impressive high transmission rate allows COVID-19 conferring enormous challenge for clinicians worldwide, and developing to a pandemic level. Combined with a series of complications, a part of COVID-19 patients progress into severe cases, which critically contributes to the risk of fatality. To date, coagulopathy has been found as a prominent feature of COVID-19 and severe coagulation dysfunction may be associated with poor prognosis. Coagulopathy in COVID-19 may predispose patients to hypercoagulability-related disorders including thrombosis and even fatal vascular events. Inflammatory storm, uncontrolled inflammation-mediated endothelial injury and renin angiotensin system (RAS) dysregulation are the potential mechanisms. Ongoing efforts made to develop promising therapies provide several potential strategies for hypercoagulability in COVID-19. In this review, we introduce the clinical features of coagulation and the increased vascular thrombotic risk conferred by coagulopathy according to present reports about COVID-19. The potential underlying mechanisms and emerging therapeutic avenues are discussed, emphasizing an urgent need for effective interventions. |Acute Disease[MESH] |Anticoagulants/*therapeutic use[MESH] |Betacoronavirus/immunology/*pathogenicity[MESH] |Biomarkers/blood[MESH] |Blood Platelets/drug effects/pathology/virology[MESH] |COVID-19[MESH] |Coronavirus Infections/*complications/drug therapy/mortality/virology[MESH] |Cytokine Release Syndrome/*complications/drug therapy/mortality/virology[MESH] |Disseminated Intravascular Coagulation/*complications/drug therapy/mortality/virology[MESH] |Fibrin Fibrinogen Degradation Products/metabolism[MESH] |Heparin/therapeutic use[MESH] |Host-Pathogen Interactions/immunology[MESH] |Humans[MESH] |Lung/blood supply/drug effects/pathology/virology[MESH] |Pandemics[MESH] |Partial Thromboplastin Time[MESH] |Pneumonia, Viral/*complications/drug therapy/mortality/virology[MESH] |Pulmonary Embolism/*complications/drug therapy/mortality/virology[MESH] |Respiratory Insufficiency/*complications/drug therapy/mortality/virology[MESH] |SARS-CoV-2[MESH]Coagulopathy in COVID-19: Focus on vascular thrombotic events (epmc).pdf DeepDyve Pubget Overpricing